Company profile APRE

Aprea Therapeutics Inc
annan naturvetenskaplig och teknisk forskning och utveckling
Quarter analysis & expected interestLast update: February 08 2024 15:04:18.

After 39 days of this quarter the interest is at 19.0. Based on that we can calculate that during remaining 52 days it will total up to 44.0.
Aprea Therapeutics expected interest is significantly lower compared to same quarter last year (-65.6%) but similar to previous quarter.

YearQ1Q2Q3Q4
201929
38
31.0% QoQ
135
255.3% QoQ
123
-8.9% QoQ
2020 148
410.3% YoY 20.3% QoQ
107
181.6% YoY -27.7% QoQ
85
-37.0% YoY -20.6% QoQ
140
13.8% YoY 64.7% QoQ
2021 421
184.5% YoY 200.7% QoQ
299
179.4% YoY -29.0% QoQ
264
210.6% YoY -11.7% QoQ
163
16.4% YoY -38.3% QoQ
2022 185
-56.1% YoY 13.5% QoQ
110
-63.2% YoY -40.5% QoQ
101
-61.7% YoY -8.2% QoQ
69
-57.7% YoY -31.7% QoQ
2023 128
-30.8% YoY 85.5% QoQ
127
15.5% YoY -0.8% QoQ
95
-5.9% YoY -25.2% QoQ
38
-44.9% YoY -60.0% QoQ
2024 19
-85.2% YoY -50.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Aprea Therapeutics search interestLast update: February 08 2024 15:04:18.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:04:19.

The average 5 years interest of Aprea Therapeutics was 10.82 per week.
The last year interest of Aprea Therapeutics compared to the last 5 years has changed by -38.54%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -8.02%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ATRN-119 clinical trials to provide analysis

Correlation between past revenue and ATRN-119 clinical trials search interest

There is not enough data for ATRN-119 clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ATRN-119 clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aprea Therapeutics cancer therapeutics to provide analysis

Correlation between past revenue and Aprea Therapeutics cancer therapeutics search interest

There is not enough data for Aprea Therapeutics cancer therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aprea Therapeutics cancer therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aprea Therapeutics advanced solid tumors to provide analysis

Correlation between past revenue and Aprea Therapeutics advanced solid tumors search interest

There is not enough data for Aprea Therapeutics advanced solid tumors to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aprea Therapeutics advanced solid tumors to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aprea Therapeutics ovarian cancer to provide analysis

Correlation between past revenue and Aprea Therapeutics ovarian cancer search interest

There is not enough data for Aprea Therapeutics ovarian cancer to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aprea Therapeutics ovarian cancer to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aprea Therapeutics breast cancer to provide analysis

Correlation between past revenue and Aprea Therapeutics breast cancer search interest

There is not enough data for Aprea Therapeutics breast cancer to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aprea Therapeutics breast cancer to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aprea Therapeutics prostate cancer to provide analysis

Correlation between past revenue and Aprea Therapeutics prostate cancer search interest

There is not enough data for Aprea Therapeutics prostate cancer to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aprea Therapeutics prostate cancer to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aprea Therapeutics -stock -company to provide analysis

Correlation between past revenue and Aprea Therapeutics -stock -company search interest

There is not enough data for Aprea Therapeutics -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aprea Therapeutics -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aprea Therapeutics careers to provide analysis

Correlation between past revenue and Aprea Therapeutics careers search interest

There is not enough data for Aprea Therapeutics careers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aprea Therapeutics careers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aprea Therapeutics reviews to provide analysis

Correlation between past revenue and Aprea Therapeutics reviews search interest

There is not enough data for Aprea Therapeutics reviews to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aprea Therapeutics reviews to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for APRE
Earnings date: 2024-03-28 After close
Company name: Aprea Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T13:17:47Z

Analyst Upgrades
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

2026-05-13T10:30:00Z

GlobeNewswire
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

2026-05-07T17:27:14Z

Analyst Upgrades
This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

2026-05-07T10:49:19Z

Analyst Upgrades
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

2026-04-28T11:00:00Z

BusinessWire
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors

2026-04-21T14:15:00Z

GlobeNewswire
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

2026-04-06T12:00:00Z

BusinessWire
Frazier Life Sciences Appoints Christian Schade as Senior Advisor

2026-04-01T12:30:00Z

GlobeNewswire
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

2026-03-31T14:04:51Z

Analyst Upgrades
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

2026-03-31T11:16:24Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Lowers Price Target to $1.2

2026-03-30T12:01:00Z

GlobeNewswire
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

2026-03-30T12:00:00Z

GlobeNewswire
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

2026-03-16T12:00:00Z

GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

2026-02-18T13:00:00Z

GlobeNewswire
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

2026-02-17T13:00:00Z

GlobeNewswire
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference